“The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family”. Eur. J. Pharmacol.635 (1–3): 49–55. (2010). doi:10.1016/j.ejphar.2010.03.018. PMID20307534.
The Krause/King-Lewis acronym, developed at Naval Medical Center San DiegoArchived 2018-07-13 at the Wayback Machine., of MCRA was developed during February 2017 to distinguish between MRA for a specific MRI which are both widely recognized medical acronyms as compared to the use of MRA for mineralocorticoid receptor antagonist type medications which is only used as a medical acronym in the cardiology and nephrology word.
“The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family”. Eur. J. Pharmacol.635 (1–3): 49–55. (2010). doi:10.1016/j.ejphar.2010.03.018. PMID20307534.
The Krause/King-Lewis acronym, developed at Naval Medical Center San DiegoArchived 2018-07-13 at the Wayback Machine., of MCRA was developed during February 2017 to distinguish between MRA for a specific MRI which are both widely recognized medical acronyms as compared to the use of MRA for mineralocorticoid receptor antagonist type medications which is only used as a medical acronym in the cardiology and nephrology word.
